Beating Rectal Cancer: A 10-Year Study Reveals the Power of Combined Therapy
"New research shows that combining chemotherapy, radiation, and surgery offers a long-term advantage in treating locally advanced rectal cancer, giving hope to patients and healthcare providers alike."
Rectal cancer, when caught in its early stages, demands a strategic approach. Neoadjuvant concurrent chemoradiotherapy (NCRT) has emerged as a powerful method, improving local control and the chances of successful surgery. But what happens in the long run? Do these initial benefits translate into lasting victories against the disease?
For years, the "Mayo regimen," involving intravenous 5-fluorouracil (5-FU), has been a standard chemotherapy treatment. However, it comes with challenges like the need for injections and potential complications. Capecitabine, an oral alternative, offers a more convenient approach. Studies suggest it’s at least as safe, but questions about its long-term effectiveness have lingered.
A new study, conducted over a decade at a single institution, sheds light on the long-term outcomes of using capecitabine-based NCRT followed by surgery. It analyzes the experiences of 238 patients, offering valuable insights into survival rates, recurrence patterns, and the factors that influence success. The goal is to provide the facts, so patients and healthcare providers can make informed decisions about treatment.
Capecitabine's Clinical Role
A February 2025 review describes capecitabine as having a significant therapeutic role in colon cancer, including adjuvant and neoadjuvant therapy. It reports improved disease-free survival in stage III colon cancer compared with intravenous 5-fluorouracil (5-FU), and identifies capecitabine as central after complete resection of the primary tumor. The drug is an oral prodrug of 5-FU and can be used alone or with oxaliplatin to improve survival and slow disease progression.
Established Chemoradiotherapy Options
Treatment options can differ according to tumor location, although approaches for colon cancer and upper rectal carcinoma are similar. The Lancet review reports that most phase 3 trials comparing capecitabine with fluorouracil found capecitabine to be at least as effective. For locally advanced rectal cancer, one 2025 clinical summary describes capecitabine at 825 mg/m² twice daily on weekdays during concurrent 45-50.4 Gy radiation as an acceptable alternative to infusional 5-FU, while noting that treatment approaches remain dependent on clinical context.
A Century of Treatment Evolution
Rectal cancer management has changed substantially over the last century. A 2024 review attributes this evolution to advances in surgical techniques, radiotherapy technologies, new drugs, supportive care, and clinical research methods. Capecitabine, identified as the third-generation orally available fluoropyrimidine Xeloda by Hoffmann-La Roche in Basel, has approved indications for front-line treatment of advanced or metastatic colorectal cancer. Recent work also emphasizes patient involvement in decisions about locally advanced rectal cancer treatment.
Decoding the Long-Term Impact of Capecitabine in Rectal Cancer Treatment
The study, conducted between 2000 and 2010, focused on patients with locally advanced rectal cancer who underwent NCRT with capecitabine and subsequent radical surgery. Researchers tracked their progress, looking at overall survival, disease-free survival, local recurrence (cancer returning near the original site), and systemic recurrence (cancer spreading to other parts of the body).
- Tolerable Toxicity: Only a small percentage (4.6%) experienced significant (Grade >3) side effects related to capecitabine.
- Pathological Complete Response (pCR): Nearly 15% of patients showed no signs of cancer in their surgical samples, indicating a strong initial response to the treatment.
- Encouraging Survival Rates: The 5-year overall survival rate was an impressive 82.8%, with a 75.1% 5-year disease-free survival rate.
- Low Local Recurrence: Cancer returned locally in only 4.8% of cases.
- Systemic Recurrence: Cancer spread to other areas in 20.3% of patients.
- Key Risk Factors: The need for abdominoperineal resection (removal of the anus, rectum, and part of the colon) and the presence of node-positive disease (cancer in nearby lymph nodes) were identified as factors associated with poorer outcomes.
Current Research Directions
Recent research is examining how treatment decisions can be refined for mid and low rectal cancer. A 2025 retrospective comparative cohort study focuses on lateral pelvic lymph node dissection based on nodal response to neoadjuvant chemoradiotherapy. Its abstract describes local recurrence as a critical issue associated with considerable morbidity and high mortality. A separate review evaluates late-phase clinical trials published from January 2024 through March 2025 across chemotherapy, immunotherapy, targeted therapy, metastatic colorectal cancer, and locally advanced rectal cancer.
Limits of Long-Term Evidence
Long-term evidence for homogeneous groups treated with neoadjuvant chemoradiotherapy using capecitabine has been described as lacking. A single-institution study therefore evaluated 10-year oncologic outcomes after capecitabine-based neoadjuvant chemoradiotherapy and radical surgery. However, the related report describes its design as noncomparative and retrospective. It states that, although favorable oncologic results were reported, the study could not establish capecitabine's superiority.
Capecitabine and Infusional 5-FU
A 2018 comparative review reports that continuous intravenous infusion 5-FU regimens had an improved safety profile compared with capecitabine-based regimens. Its findings suggest that continuous-infusion 5-FU remained a more effective and safer fluorouracil administration method in colorectal cancer management. Separately, a study conducted at a university hospital from 2002 to 2016 compared capecitabine alone with capecitabine plus oxaliplatin, known as XELOX, as neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Cardiotoxicity is also identified as an uncommon but potentially lethal complication of both 5-FU and capecitabine treatment.
The Future of Rectal Cancer Treatment: Capecitabine and Beyond
This study adds to the growing body of evidence supporting the use of capecitabine in NCRT for rectal cancer. Its convenience, manageable side effects, and promising long-term outcomes make it a valuable tool in the fight against this disease.
Salvage Therapy and Real-World Testing
Future research includes evaluating capecitabine as salvage treatment for metastatic colorectal cancer after progression on prior standard 5-FU-containing chemotherapy. A January 2023 study aimed to retrospectively analyze its efficacy and toxicity in that setting. Another study is assessing the real-world tolerability of capecitabine plus oxaliplatin, or CAPOX, in a single-institution cohort of patients with localized colorectal cancer receiving curative-intent treatment. Together, these studies extend investigation beyond initial therapy into later-line care and routine clinical practice.
A Decade of Patient Outcomes
A single-institution study examined the long-term oncologic outcomes of neoadjuvant concurrent chemoradiotherapy with capecitabine followed by radical surgery in locally advanced rectal cancer. Its stated aim was to evaluate outcomes over 10 years. Because the evidence comes from a single institution and the broader report is retrospective and noncomparative, the findings describe observed long-term results rather than proving that capecitabine is superior to other treatments. The study nevertheless provides a real-world perspective on extended follow-up after combined therapy.
While the results are encouraging, it's important to remember that this was a single-institution study. Further research, especially large, randomized controlled trials, is needed to confirm these findings and compare capecitabine to other treatment approaches.
The findings offer hope that personalized treatment strategies can be tailored to individual patients, maximizing their chances of long-term survival and a good quality of life. By understanding the factors that influence outcomes, doctors can better guide treatment decisions and improve the lives of those affected by rectal cancer.